ADA1A_BOVIN ADRA1C ELISA tesk kit
- Known as:
- ADA1A_BOVIN ADRA1C Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16708
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- ADA1A_BOVIN ADRA1C ELISA tesk kit
Related genes to: ADA1A_BOVIN ADRA1C ELISA tesk kit
- Gene:
- ADRA1A NIH gene
- Name:
- adrenoceptor alpha 1A
- Previous symbol:
- ADRA1C
- Synonyms:
- ADRA1L1
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-19
- Date modifiied:
- 2019-03-22
Related products to: ADA1A_BOVIN ADRA1C ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: ADA1A_BOVIN ADRA1C ELISA tesk kit
- Chronic hypersensitivity pneumonitis (CHP) is an inflammatory lung disease that, upon persistent antigen exposure, progresses to fibrosis and increases the risk of lung cancer (LC). This study explores the shared molecular signatures between CHP and LC, emphasizing the role of collagen-associated genes in disease progression. Transcriptomic profiling identified 158 common differentially expressed genes, with network analysis revealing nine hub genes, COL10A1, COL22A1, COL7A1, COL5A2, COL17A1, GPR17, CCK, ADRA1A, and EDNRB, predominantly enriched in pathways related to collagen biosynthesis and extracellular matrix (ECM) organization. Significant upregulation of five collagen genes (COL10A1, COL22A1, COL7A1, COL5A2, and COL17A1) was observed, and these in silico findings were validated experimentally using bronchoalveolar lavage fluid samples from CHP (n = 7), lung cancer (n = 8), and control subjects (n = 7). Drug-gene interaction analysis identified albuterol sulfate as a potential candidate targeting collagen-related pathways. Molecular docking revealed a moderate binding affinity between albuterol sulfate and collagen, suggesting a plausible role in ECM modulation. Pharmacokinetic and ADMET analyses indicated favorable oral bioavailability (bioavailability score: 0.17) and low toxicity. In vitro validation demonstrated that albuterol sulfate (salbutamol) exhibited moderate cytotoxicity toward A549 lung cancer cells (IC₅₀ = 150 µg/mL) with markedly reduced toxicity in WI38 normal lung fibroblasts, supporting its selective anticancer activity with minimal effects on normal human cells. Overall, this study highlights the central role of collagen dysregulation in linking CHP and LC, and demonstrates how integrating in silico, in vitro, and clinical analyses, together with molecular docking approaches, can uncover novel therapeutic insights for fibrotic and oncogenic pathologies. - Source: PubMed
Publication date: 2026/02/21
Dasgupta SanjuktaSaha BishnupriyaChakrabarty SubhenduDas AmlanGhosh MoupiyaPaul PalashChowdhury Sushmita RoyChaudhury Koel - GPR81 (HCAR1) is a lactate-sensing G protein-coupled receptor (GPCR) involved in tumor progression, immune evasion, and therapeutic resistance across various cancers. Despite their clinical relevance and druggable nature, selective HCAR1 antagonists have yet to be identified. This study aimed to construct a statistically significant Support Vector Machine (SVM) model for binary classification (agonists versus antagonists) of HCAR1's potential ligands and the prioritization of molecular substructures driving antagonism and receptor selectivity. An SVM model was trained on 144 ligands (66 agonists, 78 antagonists), listed in the IUPHAR/BPS Guide to Pharmacology, from 12 structurally related Class A GPCRs (HCAR1, HCAR2, HCAR3, OXER1, GPR35, SUCNR1, P2Y2, MCHR1, OPRD1, AGTR1, ADORA2A, and ADRA1A). Their ligands were encoded using physicochemical descriptors, 2048-bit ECFP4 fingerprints, and ΔAffinity scores from molecular docking to active and inactive receptor conformations. The data set was split 80/20 for training and testing, respectively, with hyperparameters (, γ) being optimized via 5-fold cross-validation. SHAP analysis was performed for feature interpretation. The final SVM model achieved a test set accuracy of 79.3%, with a sensitivity of 69.2% and specificity of 87.5%. The ROC analysis yielded an AUC of 0.94, while bootstrapping confirmed robust performance with a mean AUC of 0.874 and a 95% confidence interval [0.711, 1.000]. SHAP analysis highlighted polar, rigid, and aromatic substructures as selectivity-driving features. We applied the model to screen 3,377 compounds from natural products, synthetic libraries, and FDA-approved drugs, prioritizing potential HCAR1 ligands with antagonist-like features. Based on ΔAffinity, off-target scores, and prediction confidence, Ketanserin, Cryptopyranmoscatone A1 diacetate, and Cefuroxime emerged as reference ligands with promising antagonistic potential, two of which are FDA-approved drugs. Rather than representing final hits, these molecules illustrate how structural and electronic features can favor the stabilization of inactive states in HCAR1. Overall, this work presents a proof-of-concept framework that integrates conformational docking, machine learning, and substructure interpretation to elucidate the chemical and structural determinants of HCAR1 antagonism. The findings provide fragment-level insights that may guide future bioisosteric and fragment-based design of selective antagonists for lactate-driven tumors. - Source: PubMed
Publication date: 2026/02/03
Carvalho Letícia VivasSeyffert NúbiaMeyer RobertoTiwari SandeepCastro Thiago Luiz de Paula - Disorders affecting ejaculation is only one of the many factors which may contribute to the pathogenesis of infertility. The genetic etiopathogenesis underlying anejaculation is not clear. It is important to elucidate the genetic etiology of anejaculation with respect to treatment options and genetic counseling. Herein we report two cases presenting anejaculation with familial ADRA1A missense variants. To our knowledge, this is the first report in the literature. - Source: PubMed
Publication date: 2024/05/28
Sharifi ShahrashoubDursun MuratPalanduz SukruSahin AylaKadioglu Ates - We recently found that the nuclear receptor retinoic acid-related orphan nuclear receptor alpha (RORα) protects against angiotensin II-induced cardiac hypertrophy and promotes cardiomyocyte mitophagy. The underlying molecular basis for these salutary effects remains unclear. - Source: PubMed
Publication date: 2026/01/12
Nagalingam R SBeak J YKirkland L GLutze R LHuang WAkkina DGoyal MKang CZhao AAlcira BAghajanian AGerrish KKang H SJetten A MJensen B C - Bone mineral density (BMD) reduction leads to osteoporosis. Polypeptides and polysaccharides are often used individually as supplements to improve BMD; however, the efficacy of their combined use relative to single components, as well as the underlying synergistic mechanisms, remains unclear. Therefore, this study screened bovine bone collagen peptide (BBCP) and Astragalus polysaccharide (APS) based on the theories of food-medicine homology and multi-target network regulation to investigate the synergistic ameliorative effects of a BBCP/APS combination (1 : 1, w/w) on BMD and the mechanisms underlying these effects. osteoblast models, ovariectomy (OVX) rat models, and network pharmacology analyses were employed to elucidate the underlying mechanisms. , compared with BBCP or APS alone, the BBCP/APS combination significantly enhanced osteoblast proliferation by 20.3 ± 5.80% and 22.9 ± 6.15%, respectively, and markedly upregulated osteogenic markers-alkaline phosphatase, osteocalcin, and type I collagen-relative to the model group ( < 0.01). , treatment with BBCP/APS (800 mg kg) increased femoral BMD in OVX rats from 0.193 g cm (model group) to 0.411 g cm ( < 0.05) and significantly improved trabecular bone microarchitecture. Concurrently, network pharmacology analysis identified ADRA1A and ADRA2A as core targets and predicted the p38 MAPK pathway as the principal signaling pathway involved. Activation of the p38 MAPK pathway by BBCP/APS was further confirmed RT-qPCR and western blot analyses. These findings demonstrate that the BBCP/APS combination synergistically enhances BMD, overcomes single-component limitations, and provides valuable insights for functional food development. - Source: PubMed
Publication date: 2026/02/23
Wang XiaozhouSuo ShikunWang YanliPan DaodongDu LihuiWang JuanGao XinchangDang Yali